TROGENIX
LIVE

Serial Number

79421846

Owner

Trogenix Ltd

Filing Date

Jan 31, 2025

Add to watchlist:

No watchlists yet
View on USPTO

TROGENIX Trademark

Serial Number: 79421846

TROGENIX is a trademark filed by Trogenix Ltd on January 31, 2025. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics). The application is currently pending registration.

Owner Contact Info

Trogenix Ltd (3 trademarks)

Institute for Regeneration and Repair,

Entity Type: 24

Trademark Details

Filing Date

January 31, 2025

Registration Date

Not Registered

Goods & Services

Pharmaceutical, medical or veterinary preparations and substances; pharmaceutical preparations for use in targeted pharmaceutical therapies; pharmaceutical preparations and products for the treatment of neoplastic diseases; pharmaceutical preparations and products for the treatment of carcinomas and leukaemias; pharmaceutical preparations and products for the treatment of central nervous system tumours, glioblastoma, colorectal liver metastasis, squamous cell carcinomas, pancreatic cancer, melanoma, breast cancer hepatocellular carcinoma and metastatic tumours; enhancers or super-enhancers for medical or clinical use; synthetic super enhancers in gene expression cassettes for medical or clinical use; DNA sequences for medical purposes; pharmaceutical preparations for use in regenerative medicines for treatment of fibrosis, age-associated disorders, senescence, rejuvenation, neurological disease, tissue injury and tissue repair; gene therapy pharmaceuticals; pharmaceutical preparations being vectors; biotechnological preparations for medical use; biological compounds for use in the targeted pharmaceutical therapies; proteins with diagnostic and therapeutic uses; chemical and enzyme preparations for medical or veterinary purposes; reagents and substances for use in testing for medical and veterinary purposes; drug delivery agents that facilitate the delivery of pharmaceutical preparations; clinical medical reagents; diagnostic and testing preparations for clinical, medical and medical laboratory use; pharmaceuticals in the field of modulating therapeutics; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, otologic, respiratory, neurological, gastrointestinal, pancreatic, nephrologic, musculoskeletal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; biological preparations for the treatment of cancer; biological preparations for use in cell cultures for medical purposes; diagnostic biomarker reagents for medical purposes; cells for medical or clinical use; immune cells; target antigens for medical use; vaccine preparations; therapeutic vaccines.

Downloadable computer software programs; downloadable software, namely, lab information management systems; computer software platforms; downloadable software for remote diagnostics; machine learning software; machine learning software for use in genetic sequencing; algorithms, being computer software; bioinformatics software; imaging apparatus and instruments for use in the study of proteins and peptides in drug development; data processing software; downloadable computer applications in the fields of oncology, recombinant protein production, immunology, cell engineering, viral vector engineering, genetic engineering, biopharmaceuticals, molecular biology, modulating therapeutics, assay systems, antigens and in vitro assays; software for predicting protein expression; software in the fields of genomes, genetic mapping, molecular genetics, gene regulation, molecular biology, microbiology, pharmaceuticals, medicine, diagnostic preparations, vaccines, medicine, health, microorganisms, molecular sciences, bacteria, biochemicals, cells, stem cells, clinical trials, physiology, genetics, genomics, microbiome, metabolomics, metagenomics, proteomics, glycomics, biochemistry, therapeutics, targeted pharmaceutical therapies, bacteriology, gene expression, DNA sequencing, DNA screening, biochemical reagents and biochemical assays; downloadable computer software for scientific analysis of genetic sequences; software algorithms in the fields of biotechnology and modulating therapeutics; software as a medical device; artificial intelligence software in the field of healthcare.

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
May 7, 2026 NREP
REFUSAL PROCESSED BY IB
Mar 26, 2026 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 9, 2026 RFCS
REFUSAL PROCESSED BY MPU
Mar 9, 2026 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Feb 9, 2026 RFCR
NON-FINAL ACTION WRITTEN
Feb 8, 2026 CNRT
ASSIGNED TO EXAMINER
Jan 30, 2026 DOCK
APPLICATION FILING RECEIPT MAILED
Jan 29, 2026 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 29, 2026 NWOS
NEW REPRESENTATIVE AT IB RECEIVED
Nov 29, 2025 NREP
SN ASSIGNED FOR SECT 66A APPL FROM IB
Apr 17, 2025 REPR